$INTI
Inhibitor Therapeutics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517161842 Filed on May 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $280.0K $1.990M $610.0K
YoY Change -61.11% 226.23% 0.0%
% of Gross Profit
Research & Development $440.8K $818.3K $582.5K
YoY Change -27.21% 40.48% 86.1%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $719.4K $2.813M $1.194M
YoY Change -45.91% 135.51% 29.46%
Operating Profit -$719.4K -$2.813M -$1.194M
YoY Change -45.91% 135.51% 29.46%
Interest Expense $0.00 $10.00K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$720.0K -$2.800M -$1.190M
YoY Change -45.86% 135.29% 29.35%
Income Tax
% Of Pretax Income
Net Earnings -$716.4K -$2.801M -$1.194M
YoY Change -46.09% 134.53% 29.46%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 369.6M shares 353.4M shares 245.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.640M $2.340M $120.0K
YoY Change -64.5% 1850.0% 50.0%
Cash & Equivalents $1.643M $2.340M $118.6K
Short-Term Investments
Other Short-Term Assets $290.0K $300.0K $52.02K
YoY Change 477.45% 476.73% 18.97%
Inventory
Prepaid Expenses $40.98K $51.04K
Receivables
Other Receivables
Total Short-Term Assets $1.934M $2.641M $170.6K
YoY Change -58.54% 1447.62% 33.65%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $126.9K $134.3K $250.0K
YoY Change -49.23% -46.3%
Total Long-Term Assets $126.9K $134.3K $250.0K
YoY Change -49.23% -46.3%
TOTAL ASSETS
Total Short-Term Assets $1.934M $2.641M $170.6K
Total Long-Term Assets $126.9K $134.3K $250.0K
Total Assets $2.061M $2.775M $420.6K
YoY Change -58.06% 559.73% 229.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $322.3K $339.7K $647.1K
YoY Change -18.62% -47.51% 31.03%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $339.6K $395.8K $743.4K
YoY Change -45.06% -46.76% 30.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $339.6K $395.8K $743.4K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $339.6K $395.8K $743.4K
YoY Change -45.06% -46.76% 30.76%
SHAREHOLDERS EQUITY
Retained Earnings -$46.69M -$45.97M -$37.37M
YoY Change 20.66% 23.03% 12.74%
Common Stock $48.41M $48.35M $37.04M
YoY Change 12.6% 30.53% 13.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.722M $2.379M -$322.8K
YoY Change
Total Liabilities & Shareholders Equity $2.061M $2.775M $420.6K
YoY Change -58.06% 559.73% 229.46%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$716.4K -$2.801M -$1.194M
YoY Change -46.09% 134.53% 29.46%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$740.0K -$870.0K -$480.0K
YoY Change -26.73% 81.25% 71.43%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K -3.680M
YoY Change -99.09%
NET CHANGE
Cash From Operating Activities -740.0K -870.0K -480.0K
Cash From Investing Activities
Cash From Financing Activities 50.00K -3.680M
Net Change In Cash -690.0K -4.550M -480.0K
YoY Change -115.37% 847.92% 71.43%
FREE CASH FLOW
Cash From Operating Activities -$740.0K -$870.0K -$480.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
369599266 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118623
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369186766 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369186766 shares
CY2017Q1 us-gaap Assets
Assets
2775108
CY2017Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1800000
CY2017Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
2640855
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48316564
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2339817
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
36919
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
339691
CY2017Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
56116
CY2017Q1 us-gaap Liabilities
Liabilities
395807
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2775108
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
395807
CY2017Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51038
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
134253
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
2379301
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45974182
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
650000 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
353447172 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
353447172 shares
CY2016Q4 us-gaap Assets
Assets
7338095
CY2016Q4 us-gaap Assets Current
AssetsCurrent
7196519
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50167372
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
35345
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
297826
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2016Q4 us-gaap Liabilities
Liabilities
308133
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7338095
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
308133
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61097
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141576
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
7029962
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43172755
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10307
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1828493
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4545605
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1994734
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
2813072
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-2801427
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
818338
CY2017Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
11645
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3677727
CY2017Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3677727
CY2017Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
87674
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17382
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2813072
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-867878
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2017Q1 dei Trading Symbol
TradingSymbol
HPPI
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1828493
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
357644397 shares
CY2017Q1 hppi Net Settlement In Connection With Issuance Of Shares Associated With Restricted Stock Units
NetSettlementInConnectionWithIssuanceOfSharesAssociatedWithRestrictedStockUnits
3677727
CY2017Q1 hppi Fair Value Of Shares Withheld With Net Settlement Transaction
FairValueOfSharesWithheldWithNetSettlementTransaction
3677727
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-482822
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
611952
CY2016Q1 us-gaap Revenues
Revenues
0
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
1194465
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-1194465
CY2016Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
281550
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17603
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1194465
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-482822
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
582513
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
447696
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
245353270 shares

Files In Submission

Name View Source Status
0001193125-17-161842-index-headers.html Edgar Link pending
0001193125-17-161842-index.html Edgar Link pending
0001193125-17-161842.txt Edgar Link pending
0001193125-17-161842-xbrl.zip Edgar Link pending
d372685d10q.htm Edgar Link pending
d372685dex311.htm Edgar Link pending
d372685dex312.htm Edgar Link pending
d372685dex321.htm Edgar Link pending
d372685dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20170331.xml Edgar Link completed
hppi-20170331.xsd Edgar Link pending
hppi-20170331_cal.xml Edgar Link unprocessable
hppi-20170331_def.xml Edgar Link unprocessable
hppi-20170331_lab.xml Edgar Link unprocessable
hppi-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending